Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.36 USD | +5.66% | +5.00% | +21.30% |
14/05 | Transcript : Cellectar Biosciences, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
14/05 | Cellectar Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 21.14 | 94.45 | 40.57 | 16.05 | 34.04 | 120.5 | - | - |
Enterprise Value (EV) 1 | 21.14 | 94.45 | 40.57 | 16.05 | 34.04 | 120.5 | 120.5 | 120.5 |
P/E ratio | -1.22 x | -2.74 x | -1.54 x | -0.42 x | -0.89 x | -1.78 x | -5.83 x | 21 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - | 2.72 x | 1.3 x |
EV / Revenue | - | - | - | - | - | - | 2.72 x | 1.3 x |
EV / EBITDA | - | - | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 940 | 4,541 | 6,110 | 9,385 | 12,288 | 35,849 | - | - |
Reference price 2 | 22.50 | 20.80 | 6.640 | 1.710 | 2.770 | 3.360 | 3.360 | 3.360 |
Announcement Date | 09/03/20 | 02/03/21 | 21/03/22 | 09/03/23 | 27/03/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | 44.27 | 92.88 |
EBITDA | - | - | - | - | - | - | - | - |
EBIT 1 | -14.18 | -15.29 | -24.13 | -28.81 | -38.96 | -51.19 | -32.06 | 16.16 |
Operating Margin | - | - | - | - | - | - | -72.41% | 17.4% |
Earnings before Tax (EBT) 1 | -14.09 | -15.09 | -24.12 | -28.66 | -38.04 | -46.58 | -9.05 | 31.43 |
Net income 1 | -14.09 | -15.09 | -24.12 | -28.6 | -37.98 | -65.36 | -22.6 | 14.15 |
Net margin | - | - | - | - | - | - | -51.05% | 15.24% |
EPS 2 | -18.40 | -7.600 | -4.300 | -4.050 | -3.110 | -1.890 | -0.5767 | 0.1600 |
Free Cash Flow | - | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 09/03/20 | 02/03/21 | 21/03/22 | 09/03/23 | 27/03/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -5.923 | -6.14 | -7.436 | -7.815 | -7.423 | -8.705 | -8.294 | -9.413 | -12.55 | 12 | -13.06 | -14.52 | -16.2 | -17.5 | -15.4 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -513.33% |
Earnings before Tax (EBT) 1 | -5.918 | -6.14 | -7.435 | -7.811 | -7.275 | -8.581 | -8.221 | -13.73 | -7.509 | -21.58 | -13.1 | -13.38 | -13.96 | - | - |
Net income 1 | -5.918 | -6.14 | -7.435 | -7.811 | -7.215 | -8.581 | -8.221 | -13.73 | -7.449 | -21.58 | -13.06 | -14.52 | -16.2 | -17.5 | -15.4 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -513.33% |
EPS 2 | -0.9000 | -1.000 | -1.220 | -1.280 | -0.5500 | -0.7600 | -0.7300 | -1.210 | -0.4000 | -0.7400 | -0.3700 | -0.3700 | -0.4100 | -0.5000 | -0.4000 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 21/03/22 | 10/05/22 | 05/08/22 | 03/11/22 | 09/03/23 | 04/05/23 | 14/08/23 | 13/11/23 | 27/03/24 | 14/05/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - | - |
Announcement Date | 09/03/20 | 02/03/21 | 21/03/22 | 09/03/23 | 27/03/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.30% | 120M | |
+35.01% | 709B | |
+28.08% | 595B | |
-2.60% | 367B | |
+20.83% | 334B | |
+5.69% | 289B | |
+14.77% | 239B | |
+9.41% | 211B | |
-3.72% | 203B | |
+10.77% | 171B |
- Stock Market
- Equities
- CLRB Stock
- Financials Cellectar Biosciences, Inc.